

any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 500862000105. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: August 3, 2001

By:

Michael R. Ward

Michael R. Ward  
Registration No. 38,651

Morrison & Foerster LLP  
425 Market Street  
San Francisco, California 94105-2482  
Telephone: (415) 268-6237  
Facsimile: (415) 268-7522

VERSION WITH MARKINGS TO SHOW CHANGES MADE

[SUPER-GLOBULINS FOR *IN VIVO* EXTENDED LIFETIMES]  
REACTIVELY MODIFIED THERAPEUTIC COMPOUNDS HAVING  
AN EXTENDED LIFETIME IN VIVO

[This application is a continuation-in-part of application Serial No. 08/137,821, filed October 15, 1993, which application was a continuation-in-part of application Serial No. 08/070,092, filed May 27, 1993, which was a continuation-in-part of application Serial No. 07/592,214, filed October 3, 1990.]

This application is a Continuation Application of 09/539,766 filed March 31, 2000; which is a Continuation Application 08/477,900 filed June 7 1995 now Patent No. 6,103,233; which is a Continuation Application of 08/237,346 filed May 3, 1994 now US Patent No. 5,612,034; which is a Continuation-in-Part Application of 08/137,821 filed October 15, 1993 (Abandoned).

INTRODUCTION

Technical Field

The field of this invention is agent, particularly therapeutic agent, delivery in a mammalian host.

Background

Delivery of therapeutic agents to a mammalian host can frequently be as important as the activity of the drug in providing effective treatment. For the most part, drugs are delivered orally, frequently initially at a dosage below the therapeutic dosage and by repetitive administration of the drug, the dosage is raised to a therapeutic level or a level exceeding the therapeutic level. In many cases, the fact of having a dosage above therapeutic level provides for adverse effects, since most drugs are not only